AUS
NZ
UK
CA
USA
IND
Highlights
- BlinkLab collaborates with Monash University on a groundbreaking autism and ADHD study.
- The study utilizes eye-tracking tech to identify unique markers in children with autism and ADHD.
- MAGNET project to explore data-driven methods for more precise, personalized diagnoses.
BlinkLab (ASX:BB1) has entered into a promising collaboration with Monash University, aiming to push the boundaries of autism and ADHD diagnosis through innovative eye-tracking technology. This research, conducted as part of the large-scale Monash MAGNET study, intends to assess the potential of BlinkLab’s software in detecting unique eye movement patterns associated with these neurodevelopmental conditions.
The MAGNET study, led by Monash University’s Turner Institute, seeks to recruit 1,000 families with children diagnosed with autism, ADHD, or both. BlinkLab’s role in the study focuses on “deep sensory phenotyping,” examining how specific eye movement data can serve as biomarkers for these conditions. The technology could provide a non-invasive, accurate alternative to traditional diagnostic methods, which often rely on behavioral assessments and lengthy evaluations.
BlinkLab’s diagnostic software, BlinkLab Dx 1, analyzes children’s eye movements, drawing from research that suggests those with autism and ADHD demonstrate distinct eye behaviors not typically found in neurotypical individuals. These unique patterns may provide valuable insights into the symptoms and potential subtypes of autism and ADHD, contributing to a clearer understanding of these complex conditions. According to BlinkLab’s statement, the project aims to unearth novel data clusters that could lead to more precise and personalized diagnostic tools in the future.
As part of the MAGNET study, BlinkLab will explore how its digital biomarkers, including the PPI (Pre-Pulse Inhibition) measure, align with other established behavioral, neurocognitive, and neuroimaging markers. The research could also delve into genetic factors, adding another layer of insight. Dr. Henk-Jan Boele, CEO of BlinkLab, expressed optimism about the potential of this partnership with Monash University, underscoring that the technology’s machine learning capabilities may reveal subtypes and clusters within these conditions that existing diagnostic methods have yet to identify.
The study's potential impact is significant, with hopes that this advanced approach could streamline autism and ADHD diagnosis. BlinkLab’s collaboration with Monash may pave the way for a new era in how these neurodevelopmental conditions are understood and diagnosed, ultimately benefiting families and healthcare providers seeking more accurate diagnostic tools.
Currently, BlinkLab’s shares are trading at 31 cents per share, reflecting the growing interest in its innovative approach to neurological research and diagnostics.
